BRCA1 and ovarian cancer: Individuals harboring heterozygous germline mutations in either BRCA1 or BRCA2 (collectively denoted as “BRCA1/2” hereafter) display heightened susceptibility to certain malignancies, especially breast and ovarian cancers (Ford et al, 1994; Ford et al, 1998) that arise upon loss of the remaining wild-type BRCA1/2 alleles and the onset of extensive genome instability (Brose et al, 2002; Hall et al, 1990; Miki et al, 1994; van der Kolk et al, 2010).